Literature DB >> 8184968

Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men.

C M Florkowski1, A M Richards, E A Espiner, T G Yandle, C Frampton.   

Abstract

Brain natriuretic peptide (BNP) is a recently identified hormone that is secreted by the human heart and circulates in plasma with natriuretic, endocrine, and hemodynamic effects similar to those of atrial natriuretic peptide (ANP). To examine the interaction of human BNP with ANP, we studied eight normal men receiving constant infusions of ANP (2.0 pmol.kg-1.min-1 for 5 h), with and without superimposed infusions of BNP (2.0 pmol.kg-1.min-1 for 2 h), using a balanced random-order design. BNP infusions achieved plasma levels of 30-35 pmol/l at 90-120 min and were similar to levels observed in mild heart failure. Metabolic clearance rate of BNP (mean 4.6 +/- 0.4 l/min) and disappearance rate from plasma (t1/2 18.9 min) were similar to values determined previously in the absence of exogenous ANP. In contrast, the addition of BNP induced a progressive and reversible increase (50%) in steady-state plasma ANP. Compared with ANP alone, BNP induced an additional (50%) increase in sodium excretion (P < 0.05) and significant increases in both plasma (P < 0.001) and urine guanosine 3',5'-cyclic monophosphate (P < 0.01). Systolic blood pressure was lowered by the addition of BNP (P < 0.01) and continued to fall after cessation of BNP infusions. Despite this, the response of the renin-aldosterone and sympathetic nervous systems (heart rate and plasma catecholamines) was not significantly different on the two study days. As well as showing additive effects of the two natriuretic peptides, these studies point to important interactions of BNP on ANP metabolism at plasma levels observed in mild heart failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8184968     DOI: 10.1152/ajpregu.1994.266.4.R1244

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Natriuretic peptides: are these new links in the hepatorenal connections?

Authors:  F Wong; L Blendis
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

2.  Acute salt loading and cardiotonic steroids in resistant hypertension.

Authors:  Igor V Emelyanov; Alexandra O Konradi; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov
Journal:  Curr Top Membr       Date:  2019-02-18       Impact factor: 3.049

3.  Elevated plasma concentrations of atrial and brain natriuretic peptide in type 1 diabetic subjects.

Authors:  K McKenna; D Smith; M Sherlock; K Moore; E O'Brien; W Tormey; C J Thompson
Journal:  Ir J Med Sci       Date:  2005 Jul-Sep       Impact factor: 1.568

4.  ANP is cleared much faster than BNP in patients with congestive heart failure.

Authors:  Kuniko Kimura; Yukinari Yamaguchi; Manabu Horii; Hiroyuki Kawata; Hiromitsu Yamamoto; Shiro Uemura; Yoshihiko Saito
Journal:  Eur J Clin Pharmacol       Date:  2007-05-04       Impact factor: 2.953

5.  Age-associated increase in salt sensitivity is accompanied by a shift in the atrial natriuretic peptide modulation of the effect of marinobufagenin on renal and vascular sodium pump.

Authors:  Olga V Fedorova; Vladimir A Kashkin; Irina O Zakharova; Edward G Lakatta; Alexei Y Bagrov
Journal:  J Hypertens       Date:  2012-09       Impact factor: 4.844

6.  Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.

Authors:  Erica M Dillon; Shouzuo D Wei; Deepak K Gupta; Hui Nian; Brooks S Rodibaugh; Katherine N Bachmann; Allen J Naftilan; Lynne W Stevenson; Nancy J Brown
Journal:  J Card Fail       Date:  2021-06-13       Impact factor: 5.712

7.  ANP and BNP responses to dehydration in the one-humped camel and effects of blocking the renin-angiotensin system.

Authors:  Abdu Adem; Mahmoud Al Haj; Sheela Benedict; Javed Yasin; Nicolas Nagelkerke; Fred Nyberg; Tim G Yandle; Chris M Frampton; Lynley K Lewis; M Gary Nicholls; Elsadig Kazzam
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.